Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Modified Release Tolcapone in Healthy Subjects
NCT03633591Phase 1Completed
- Sponsor
- Corino Therapeutics
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolcapone in transthyretin amyloidosis (ATTR), sponsored by Corino Therapeutics. Primary endpoints: Time to maximum concentration at 24 hours and Maximum observed concentration at 24 hours. Started Jun 2018; status: completed.
02
Drugs
tolcapone
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT03633591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633591.